Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T17:27:45.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision: v3.3.1 was added and revision: v3.2.0 was removed.
    Difference
    0.1%
    Check dated 2025-11-24T13:43:19.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The government funding/status notice banner was removed from the page, and it does not affect the trial record or data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:28:27.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Difference
    0.1%
    Check dated 2025-11-03T01:10:31.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.
    Difference
    9%
    Check dated 2025-10-05T09:57:14.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0.
    Difference
    0.2%
    Check dated 2025-09-28T03:09:59.000Z thumbnail image

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.